| References |
1. U.S. Food and Drug Administration. Drugs@FDA: FDA Approved Drug Products. Available at:; https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. https://www.accessdata.fda.gov/drugsatfda_docs/nda/96/alteplase_toc.cfm 2. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587. 3. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP,Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G, Bluhmki E, Wilhelm M, Hamilton S; ATLANTIS Trials Investigators; ECASS Trials Investigators; NINDS rt-PA Study Group Investigators. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet.2004;363:768 -774. 4. Powers WJ, Rabinstein, Ackerson, Adeoye, Bambakidis, Becker, Biller, Brown, Demaerschalk, Hoh, Jauch, Chelsea S Kidwell, Thabele M Leslie-Mazwi, Bruce Ovbiagele, Phillip A Scott, Kevin N Sheth, Andrew M Southerland, Summers, Tirschwell. Guidelines for the Early Management of Patients with. Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019 Dec;50(12):e344-e4185. Thomalla G, Simonsen CZ, Boutitie F, Andersen G, Berthezene Y, Cheng B, Cheripelli B, Cho TH, Fazekas F, Fiehler J, et al; WAKE-UP Investigators. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379:611-622. |
